Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02878785 · ClinicalTrials.gov registry record · Phase 1
Decitabine and Talazoparib in Untreated AML and R/R AML
A Phase 1 study, sponsored by University of Maryland, Baltimore.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT02878785 is a Phase 1 study that has completed, run by University of Maryland, Baltimore. The registered enrollment target is 25 participants.
The verdict
NCT02878785, a Phase 1 study, has completed, sponsored by University of Maryland, Baltimore.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
The purpose of this study is to find the best way to combine a new chemotherapy drug with one that is already in use to treat AML. The new experimental drug is called talazoparib (also known as BMN-673), and it is not approved by the Federal Drug Administration (FDA). The FDA is allowing the use of talazoparib for the purposes of this study. Decitabine is used to treat bone marrow diseases called myelodysplastic syndromes (MDS), as well as off label for AML. Lab work suggests that talazoparib will increase the effects of decitabine in leukemia cells. Investigators hope that treating patients with decitabine and talazoparib together will be more successful that treating patients with decitabine alone. This study has two parts. The purpose of part one the study is to find out the best doses of decitabine and talazoparib to use when they are given together to treat AML. The purpose of part two is to see how well the drugs work together to treat AML. All participants in the study will be treated with decitabine and talazoparib. Part one of the study will include as few as two people and as many as 36 people to find the best dose levels of the study drugs. Part one will begin enrolling first. Part two of the study will not start until the Part one of the study is complete. Participants will be told which part of the study they may be enrolled in. Part two of the study may include as few as 79 people and as many as 135 people. Part two includes three separate arms. Participants enrolled in Part two of the study, will be assigned to one of the three arms below in order to test the success rate of the study drug dose determined by Part one: * Arm A will enroll adult patients with AML who are thought not to be likely to tolerate or respond to standard chemotherapy; * Arm B will enroll adult patients with AML that has not responded to previous treatment or has come back after responding to previous treatment; * Arm C will enroll adult patients previously treated with a
Interventions
- DRUG Decitabine
- DRUG talazoparib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2016-08 |
| Est. Completion | 2020-11-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02878785
The ClinicalTrials.gov registry entry for NCT02878785 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Decitabine is the first listed.
NCT02878785 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02878785 about?
NCT02878785 is a clinical study titled "Decitabine and Talazoparib in Untreated AML and R/R AML". The purpose of this study is to find the best way to combine a new chemotherapy drug with one that is already in use to treat AML. The new experimental drug is called talazoparib (also known as BMN-673), and it is not approved by the Federal Drug Administration (FDA). The FDA is allowing the use of ...
What is the current status of trial NCT02878785?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2016-08. Estimated completion is 2020-11-19.
What interventions are being tested in trial NCT02878785?
The interventions under investigation include: Decitabine (DRUG), talazoparib (DRUG).
Who is sponsoring clinical trial NCT02878785?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.